GlassScriptPhysician profile
Thomas R Mccune
NPI 1154310050
$202,025.03
in general payments reported to CMS, 2019-2025
33 companies · $2,926 in 2025
The $2,926 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116K · 2020: $45K · 2021: $26K · 2022: $10K · 2023: $966 · 2024: $1,234 · 2025: $2,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,460 · Food and Beverage: $1,784 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $548 · Education: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,460.00 |
| Food and Beverage | $1,784.33 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $548.00 |
| Education | $333.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $190,320.15 | 2019-2024 | Jynarque |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $5,208.40 | 2019-2025 | |
| Genzyme Corporation | $3,681.53 | 2020-2023 | |
| Amgen INC. | $439.73 | 2023-2025 | Tavneos, Krystexxa, Parsabiv |
| Astrazeneca Pharmaceuticals LP | $344.72 | 2019-2025 | Farxiga, Lokelma, Evusheld |
| Travere Therapeutics, INC. | $258.43 | 2022-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $185.40 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $169.83 | 2019-2023 | Velphoro |
| Vifor Pharma, INC. | $137.07 | 2019-2022 | |
| Akebia Therapeutics INC | $122.25 | 2019-2025 | Auryxia, Vafseo |
| Opko Pharmaceuticals, LLC | $111.68 | 2019-2024 | Rayaldee |
| Glaxosmithkline, LLC. | $107.44 | 2022-2023 | Benlysta |
| Novo Nordisk INC | $85.30 | 2024-2025 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $70.16 | 2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $69.92 | 2022-2025 | Tarpeyo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $65.95 | 2022-2024 | Livtencity |
| Alexion Pharmaceuticals, INC. | $64.01 | 2022-2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $62.56 | 2023-2024 | |
| Ardelyx, INC. | $61.98 | 2024-2025 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $58.19 | 2025 | Givlaari, Oxlumo |
| Ani Pharmaceuticals, INC. | $55.99 | 2024 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $55.51 | 2024-2025 | Crysvita |
| Veloxis Pharmaceuticals, INC. | $47.61 | 2019-2023 | Envarsus |
| Mallinckrodt Hospital Products INC. | $36.16 | 2024 | Acthar |
| Aurinia Pharma U.S., INC. | $35.11 | 2021-2023 | Lupkynis |
| Mallinckrodt Enterprises LLC | $32.36 | 2019 | |
| Sanofi-Aventis U.S. LLC | $26.25 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $24.58 | 2020 | |
| Cormedix INC. | $24.52 | 2025 | Defencath |
| Ultragenyx Pharmaceutical INC. | $23.17 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.53 | 2024 | Jardiance |
| Baxter Healthcare | $17.54 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mccune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.